ǥ :
|
ȣ - 500748 37 |
Long-Term Outcomes After Sirolimus-Eluting Stent Implantation |
계명대학교 동산의료원 심장내과 |
조현옥, 남창욱, 허승호, 김권배, 이현숙, 전동환, 조윤경, 김형섭, 한성욱, 김윤년 |
Background: Sirolimus-eluting stent (SES) is generally known as the powerful suppression of neointimal hyperplasia. In selected cases, the safety and efficacy of SES were revealed until 4 years. We would like to have the evidence of promising results at long-term (2 year) follow-up in real world practice.
Method: 692 patients (male 66.3%, age 61 ± 10) were consecutively enrolled who underwent coronary intervention with SES since April 2003 to July 2004. 2 years clinical outcomes and angiographic follow-up results were analyzed, and were compared with the pooled data of bare metal stent, which were implanted since January 2003 to December.
Results: 2 years adverse cardiac events were 4.6 % in SES, 12.8 % in BMS (p<0.001). Other data are in the following table. 2 years clinical follow-up was available 87.3%. Angiographic follow up was available in 54.2%.
Conclusion: This analysis of 2 year data collected by single center experience in real world practice suggests a high degree of safety and efficacy of SES, with a similar rate of stent thrombosis in BMS.
|
Table.
Clinical and Angiographic outcomes
%
(n) |
Group
1 (SES) |
Group
2 (BMS) |
P
value |
Patients
/ Lesions, (n) |
375
/ 544 |
217
/ 292 |
? |
1
year Death, (%) |
1
(0.2) |
4
(1.4) |
0.055 |
1
year MACE, (%) |
16
(3.1) |
32
(11.3) |
<0.001 |
2
year Death, (%) |
4
(0.9) |
5
(1.8) |
0.212 |
2
year MACE, (%) |
21
(4.6) |
35
(12.8) |
<0.001 |
Stent
thrombosis, (%) |
5
(1.1) |
8
(2.9) |
0.084 |
ISR,
(%) |
16
(5.4) |
40
(29.2) |
<0.001 |
MACE; major adverse cardiac event, ISR; in-stent restenosis, BMS; bare
metal stent
|
|
|